Assessment of biomarkers and clinical parameters as predictors of survival in patients with chagasic heart failure

Imagem de Miniatura
Arquivos
art_BOCCHI_Assessment_of_biomarkers_and_clinical_parameters_as_predictors_2023.PDF (709.88 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
NAKANISHI, Erika Shimoda
Citação
PLOS NEGLECTED TROPICAL DISEASES, v.17, n.12, article ID e0011847, 12p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Chagas disease, endemic in Latin America and spreading globally due to emigration, has a significant health burden, particularly in relation to chagasic heart failure (HF). Chagasic cardiomyopathy (CCM) is characterized by chronic inflammatory myocardial disease. This study aimed to identify inflammatory parameters and biomarkers that could aid in the management of patients with chagasic HF. Methods and findings A cohort study was conducted at a tertiary cardiology single-center over a mean follow-up period of 2.4 years. The study included patients with HF secondary to CCM enrolled between October 2013 and July 2017. Various clinical parameters, echocardiography findings, parasitemia status, brain natriuretic peptide (BNP) and troponin T (TnT) levels, and inflammatory biomarkers (IL-6, IL-10, IL-12p70, IL-17A, adiponectin, and IFN-gamma) were assessed. The study encompassed a cohort of 103 patients, with a median age of 53 years and 70% being male. The left ventricular ejection fraction (LVEF) was 28%, with 40% of patients classified as NYHA II functional class. The median BNP level was 291 pg/ml. The observed mortality rate during the study period was 38.8%. Predictors of lower survival were identified as elevated levels of BNP, TnT, reduced LVEF, and increased adiponectin (thresholds: BNP > 309 pg/ml, TnT > 27.5 ng/ml, LVEF < 25.5%, adiponectin > 38 mu g/mL). Notably, there was no evidence indicating a relationship between parasitemia and the inflammatory parameters with lower survival in these patients, including INF-gamma, IL-6, IL-10, IL12-(p70), and IL17a. Conclusion Despite the presence of a chronic inflammatory process, the evaluated inflammatory biomarkers in this cohort were not predictive of survival in patients with chagasic HF with reduced ejection fraction (HFrEF). However, reduced LVEF, elevated BNP, adiponectin levels, and troponin T were identified as predictors of lower survival in these patients.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/58810
Referências
  1. Ahmad T, 2012, NAT REV CARDIOL, V9, P347, DOI 10.1038/nrcardio.2012.37
  2. [Anonymous], 2015, Wkly Epidemiol Rec, V90, P33
  3. Barbosa-Ferreira JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131447
  4. Benvenuti LA, 2008, ANN TROP MED PARASIT, V102, P481, DOI 10.1179/136485908X311740
  5. Benziger CP, 2017, CARDIOL CLIN, V35, P31, DOI 10.1016/j.ccl.2016.08.013
  6. Bocchi EA, 2013, J AM COLL CARDIOL, V62, P949, DOI 10.1016/j.jacc.2013.06.013
  7. Bosch-Nicolau P, 2022, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.787214
  8. Tobar IB, 2011, REV SOC BRAS MED TRO, V44, P691, DOI 10.1590/S0037-86822011000600008
  9. Celik T, 2010, INT J CARDIOL, V144, P319, DOI 10.1016/j.ijcard.2009.03.006
  10. D'Avila DA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208133
  11. Echeverría LE, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0258622
  12. Hasslocher-Moreno AM, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100694
  13. Horwich TB, 2003, CIRCULATION, V108, P833, DOI 10.1161/01.CIR.0000084543.79097.34
  14. de Souza ACJ, 2015, INT J CARDIOL, V187, P700, DOI 10.1016/j.ijcard.2015.03.372
  15. Kociol RD, 2010, J AM COLL CARDIOL, V56, P1071, DOI 10.1016/j.jacc.2010.06.016
  16. Lima-Costa MF, 2010, AM J EPIDEMIOL, V172, P190, DOI 10.1093/aje/kwq106
  17. LIMAS CJ, 1995, CIRCULATION, V91, P631, DOI 10.1161/01.CIR.91.3.631
  18. López L, 2006, REV ESP CARDIOL, V59, P50, DOI 10.1157/13083649
  19. Magalhaes LMD, 2022, LANCET MICROBE, V3, pE711, DOI 10.1016/S2666-5247(21)00265-2
  20. Maldonado E, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/4993452
  21. Marin-Neto JA, 2022, PREPRINT, DOI [10.1590/SciELOPreprints.4820, DOI 10.1590/SCIELOPREPRINTS.4820]
  22. Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574
  23. Murphy SP, 2020, J AM COLL CARDIOL, V75, P1324, DOI 10.1016/j.jacc.2020.01.014
  24. O'Connor CM, 2011, NEW ENGL J MED, V365, P32, DOI 10.1056/NEJMoa1100171
  25. Nunes MCP, 2018, CIRCULATION, V138, pE169, DOI 10.1161/CIR.0000000000000599
  26. Pfisterer M, 2009, JAMA-J AM MED ASSOC, V301, P383, DOI 10.1001/jama.2009.2
  27. Poveda C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091154
  28. Rassi A, 2006, NEW ENGL J MED, V355, P799, DOI 10.1056/NEJMoa053241
  29. Rauchhaus M, 2000, CIRCULATION, V102, P3060
  30. Sabino EC, 2015, EUR J HEART FAIL, V17, P416, DOI 10.1002/ejhf.220
  31. Saravia SGM, 2013, CLIN BIOCHEM, V46, P1615, DOI 10.1016/j.clinbiochem.2013.06.011
  32. Saunders JT, 2011, CIRCULATION, V123, P1367, DOI 10.1161/CIRCULATIONAHA.110.005264
  33. Shen L, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.117.004361
  34. Sherbuk JE, 2015, GLOB HEART, V10, P173, DOI 10.1016/j.gheart.2015.07.003
  35. Sousa GR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172833
  36. Sousa GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087082
  37. Tanowitz HB., 2016, Trypanosoma cruzi and Chagas disease: innate immunity, ROS, and cardiovascular system, P183
  38. de Freitas VLT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001277
  39. Tsukamoto O, 2009, J AM COLL CARDIOL, V53, P2070, DOI 10.1016/j.jacc.2009.02.038
  40. Van Berendoncks An M, 2011, Curr Heart Fail Rep, V8, P113, DOI 10.1007/s11897-011-0056-6
  41. Van Tassell BW, 2013, CIRCULATION, V128, P1910, DOI 10.1161/CIRCULATIONAHA.113.003199
  42. Viotti R, 2006, ANN INTERN MED, V144, P724, DOI 10.7326/0003-4819-144-10-200605160-00006

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP